-
Perifosine: A Stress-Resolved Akt Assay Strategy
2026-09-08
Perifosine (KRX-0401) can do more than inhibit Akt: it enables a stress-resolved framework linking survival signaling, apoptosis, and treatment response. This article translates cerebral ischemia research into practical oncology assay decisions without overstating cross-domain evidence.
-
Polygodial: From TRPA1 Activation to Cell Signaling
2026-09-08
Polygodial is a TRPA1 channel activator that can connect proximal calcium entry with epithelial inflammatory signaling. This article presents an evidence-based framework for interpreting TRPA1 experiments, distinguishing channel activation from downstream biological effects.
-
Refining In Vitro Drug Response Metrics in Cancer
2026-09-07
Hannah R. Schwartz’s dissertation examines why conventional in vitro viability measurements can obscure the distinction between proliferative arrest and cell death. Its central contribution is a two-metric framework that separates relative viability from fractional viability, improving interpretation of drug response timing, magnitude, and mechanism in cancer research.
-
Axitinib (AG 013736): Reliable Assays
2026-09-07
Learn how Axitinib (AG 013736), SKU A8370, can improve the interpretation and reproducibility of VEGF-pathway cell assays. This scenario-based guide connects receptor potency, solution handling, viability metrics, and vendor-selection decisions to practical cancer biology workflows.
-
Perospirone (SM-9018 freebase): Assay Guide
2026-09-05
This scenario-based guide explains how Perospirone (SM-9018 freebase), SKU BA5009, can be handled and interpreted in cell viability, proliferation, cytotoxicity, and neurovascular experiments. It connects receptor pharmacology, solvent control, assay optimization, and the reported Kv1.5 interaction while distinguishing literature evidence from practical workflow recommendations.
-
Whole Blood circUSP10 for Early NSCLC Diagnosis
2026-09-04
The reference study identified hsa_circ_0003026, termed circUSP10, as an elevated circular RNA in early-stage non-small-cell lung cancer and evaluated its diagnostic potential in whole blood. Its discovery-to-validation workflow connects tissue profiling, RT-qPCR confirmation, blood-based detection, stability testing, and ROC analysis, while also highlighting the need for independent clinical validation.
-
Separating Growth Inhibition from Cancer Cell Death
2026-09-04
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central practical implication is that drug evaluation should distinguish proliferative arrest from cell killing and consider their different temporal relationships.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-09-03
HyperPFU™ high-fidelity DNA polymerase is designed for accurate PCR amplification of long, GC-rich, and otherwise difficult DNA templates. It is suitable for blunt-ended products used in cloning and sequencing, but not for workflows that require 3′-A overhangs or sticky-end products.
-
AG-221 (Enasidenib): Reliable AML Assays
2026-09-03
Learn how AG-221 (Enasidenib), SKU B7804, can support genotype-directed acute myeloid leukemia research through IDH2 R140Q inhibition, 2-hydroxyglutarate reduction, and better-controlled assay workflows. The article connects formulation, experimental design, differentiation, viability, and metabolic readouts to practical laboratory decisions.
-
Actinomycin D for mRNA Stability in AML
2026-09-02
Actinomycin D is more than a general transcriptional inhibitor: it can help distinguish altered mRNA production from altered mRNA decay in acute myeloid leukemia models. This guide connects ActD-chase assay design with IGF2BP3–EPOR biology, practical handling, and interpretation limits.
-
Insulin–AMPK Control of PINK1 in Neurons
2026-09-02
This bioRxiv preprint identifies insulin–AMPK signaling as a metabolic switch that controls mitochondrial Pink1 mRNA localization and PINK1 activity in neurons. The findings connect insulin resistance, including an ApoE4-associated in vitro model, with impaired neuronal mitophagy and provide a framework for studying metabolic regulation of mitochondrial quality control.
-
Actinomycin D in BBB mRNA Stability Research
2026-09-01
Actinomycin D can do more than suppress transcription: it can help distinguish mRNA synthesis from decay in blood–brain barrier models. This article translates RBM3–MEF2C findings into a rigorous ActD assay strategy while addressing DNA damage, apoptosis induction, and experimental limitations.
-
Matrine: From Assay Signal to Mechanism
2026-09-01
Matrine is a Sophora-derived alkaloid with anticancer, apoptotic, and anti-inflammatory research applications. This guide converts recent thymoma findings into an evidence-calibrated assay strategy that separates phenotypic activity from causal mechanism.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-08-31
The reference study positions moesin (MSN) as both a circulating indicator of endothelial injury and a mechanistic contributor to vascular barrier dysfunction in sepsis. By combining patient samples, LPS and CLP mouse models, and MSN-silenced human microvascular endothelial cells, the authors connect serum MSN with disease severity, Rock1/myosin light chain signaling, NF-κB activation, inflammation, and hyperpermeability.
-
AG-221 Workflows for IDH2-Mutant AML
2026-08-31
AG-221 (Enasidenib) enables genotype-aware AML experiments that connect 2-hydroxyglutarate reduction with differentiation and metabolic dependency. This practical guide integrates dose-response design, metabolite sampling, CD44-focused validation, and troubleshooting for more interpretable IDH2-mutant leukemia studies.